Novel Metabolic Targeting Approach to Melanoma Treament.
A Melanoma Trial is being initiated by Professor Hersey from the Sydney Melanoma Unit using a novel NACO formulation. Approval has been obtained to commence trials with Melanoma Stage 4 patients.
Information will be periodically updated on the www.jonpharma.com web site.
Clinical Trials - BRAF
Information for patients, their families and supporters
Thank you for your interest in the new treatment for melanoma.
Results of a phase I clinical trial of PLX4032, a highly selective BRAF-inhibitor, in cancer patients have been presented at the American Society of Clinical Oncoogy meeting in Orlando on the 1st of June.This agent is being developed by Plexxikon, a California-based biotechnology company, in partnership with Roche. Pharmaceuticals.
This treatment is in the very early stages of development and although early results are promising more trials are needed to the confirm results to see if the treatment should be used routinely for patients with advanced melanoma.There is no evidence that this treatment can cure people with advanced melanoma.There is also no role for this treatment at this point in melanoma that has been fully removed by surgery. Surgery remains the treatment of choice of early melanoma and can cure the majority of patients.
Information 
